Generic Ozurdex Availability
Last updated on Aug 10, 2022.
Ozurdex is a brand name of dexamethasone ophthalmic, approved by the FDA in the following formulation(s):
OZURDEX (dexamethasone - implant;intravitreal)
Has a generic version of Ozurdex been approved?
No. There is currently no therapeutically equivalent version of Ozurdex available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ozurdex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ocular implant made by a double extrusion process
Patent 10,076,526
Issued: September 18, 2018
Assignee(s): Allergan, Inc.The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Patent expiration dates:
- January 9, 2023✓
- January 9, 2023
-
Patent 10,702,539
Patent expiration dates:
- January 9, 2023✓
- January 9, 2023✓
- January 9, 2023✓
- January 9, 2023
-
Methods and apparatus for delivery of ocular implants
Patent 6,899,717
Issued: May 31, 2005
Inventor(s): Weber; David & Kane; Ingrid & Rehal; Mike & Lathrop, III; Robert L. & Aptekarev; Kenny
Assignee(s): Allergan, Inc.An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
Patent expiration dates:
- November 1, 2023✓
- November 1, 2023
-
Ocular implant made by a double extrusion process
Patent 8,034,366
Issued: October 11, 2011
Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
Assignee(s): Allergan, Inc.The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Patent expiration dates:
- January 9, 2023✓✓
- January 9, 2023✓✓
- January 9, 2023
-
Ocular implant made by a double extrusion process
Patent 8,034,370
Issued: October 11, 2011
Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
Assignee(s): Allergan, Inc.The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Patent expiration dates:
- January 9, 2023✓
- January 9, 2023
-
Ocular implant made by a double extrusion process
Patent 8,506,987
Issued: August 13, 2013
Assignee(s): Allergan, Inc.The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Patent expiration dates:
- January 9, 2023✓
- January 9, 2023✓
- January 9, 2023
-
Ocular implant made by a double extrusion process
Patent 9,192,511
Issued: November 24, 2015
Assignee(s): Allergan, Inc.The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Patent expiration dates:
- January 9, 2023✓
- January 9, 2023
More about Ozurdex (dexamethasone ophthalmic)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (7)
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: ophthalmic steroids
- FDA approval history
Patient resources
Other brands
Maxidex, Dextenza, Dexycu, Ocu-Dex
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.